Fig. 2.

Circulating asymmetric dimethylarginine (ADMA) and representative bands (two per animal from a n = 7 per group) showing renal protein expression and quantification of endothelial nitric oxide synthase (eNOS) from normal, renal angioplasty and stenting (PTRAs) and PTRAs+ elastin-like polypeptide-vascular endothelial growth factor (ELP-VEGF)-treated pigs. Intrarenal ELP-VEGF at PTRAs resulted in a significant attenuation in systemic plasma ADMA concentration (A), a potent inhibitor of eNOS. B: ADMA attenuation was accompanied by increased expression of eNOS in the PTRAs+ELP-VEGF-treated kidney. C: these improvements in mediators of endothelial function were accompanied by a significantly greater decrease in plasma creatinine concentration in PTRAs+ELP-VEGF-treated pigs compared with pretreatment values. ADMA, asymmetric dimethylarginine. *P < 0.05 versus 6 wk. #P = 0.08 versus renovascular disease (RVD) +PTRAs. †P < 0.05 versus RVD+PTRAs.